Piper Sandler reiterated an "overweight" rating and issued a $105.00 price objective on shares of CR...
JMP Securities reissued a "market outperform" rating and set a $86.00 price target on shares of CRIS...
Needham & Company LLC restated a "buy" rating and issued a $81.00 price objective on shares of CRISP...
Chardan Capital restated a "buy" rating and set a $82.00 price objective on shares of CRISPR Therape...